What You Need To Know
A team of oncology experts at Jersey Shore University Medical Center, led by Gregory J. Tiesi, M.D., FACS, FSSO, have successfully treated their first patients using RenovoRx’s novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. The academic medical center is the first hospital in New Jersey to provide TAMP to patients.
TAMP, enabled by the RenovoCath®, is a FDA-cleared device (catheter) used to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoCath is being used by clinical practitioners and is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
“Jersey Shore remains committed to adopting innovative treatments like TAMP to enhance patient care and expand access to leading-edge, precise cancer therapies,” said Kenneth N. Sable, M.D., MBA, FACEP, regional president, Southern Market, Hackensack Meridian Health. “Our experts in oncology are proud to offer this advanced option as part of all the available, comprehensive cancer care services.” These include those offered by the Hackensack Meridian John Theurer Cancer Center (JTCC) at JSUMC; leukemia care, including bone marrow transplant, and access to novel drugs or combinations of drugs as part of phase I clinical trials.
“Our patients also have access, through the JTCC, to inpatient stem cell transplantation as well as the latest cell therapy treatments, including chimeric antigen receptor T-cell (CAR-T) therapy,” Dr. Sable noted.